Ratings AXA

Equities

CS

FR0000120628

Market Closed - Euronext Paris 16:35:04 18/07/2024 BST After market 18:00:10
32.25 EUR +0.84% Intraday chart for AXA 32.31 +0.19%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • Its low valuation, with P/E ratio at 9.21 and 8.42 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.78 for the current period. Therefore, the company is undervalued.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Life & Health Insurance

1st Jan change Capi. Investor Rating ESG Refinitiv
+9.36% 76.97B
B-
+15.05% 54.17B
B+
+14.82% 53.45B
B
+23.19% 47.22B
B+
+22.04% 45.72B
B+
+23.27% 39.52B
B
+25.36% 34.87B
B
+40.33% 29.38B
A
+0.55% 29.25B
B
-6.48% 28.29B
B-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes